SEATTLE, May 28, 2021, (MEDGADGET) — Global Sarcoma Biopsy Market
A biopsy is a procedure in which a small amount of tissue is removed for examination under a microscope. Although imaging tests may suggest a sarcoma diagnosis, a biopsy is required to confirm the diagnosis and determine the type of sarcoma. To diagnose sarcomas, several types of biopsies are used, of which, the majority of which are needle biopsies, in which a needle is used to access the suspicious tissue of the sarcoma.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3819
Rising incidence of osteosarcoma (common type of cancer) is expected to augment the global sarcoma biopsy market growth over the forecast period. According to the American Cancer Society, each year, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States, of which, around 50% of cases occurs in children and young adults.
Moreover, increasing prevalence of bone cancer is expected to boost the global sarcoma biopsy market growth. According to the American Society of Clinical Oncology, in the U.S., around 3,450 new cases of bone cancer were registered and total 1,590 deaths occurred due to bone cancer in 2018.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3819
By Product Type:
- Reusable Device
- Disposable Devices
By End User:
- Ambulatory Surgical Centres
- Diagnostic Centres
- North America
- Latin America
- Asia Pacific
- Middle East, and Africa
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/sarcoma-biopsy-market-3087
North America is expected to witness robust growth in the global sarcoma biopsy market due to increasing healthcare spending in the region, especially in the United States. According the Committee for a Responsible Federal Budget, the United States spent approximately US$ 3.5 trillion, or 18% of total GDP, on health expenditures in 2017, which is more than twice the average among developed countries.
The Asia Pacific is also expected to witness substantial growth in the global sarcoma biopsy market due to increasing healthcare facilities in the region. According to the India Brand Equity Foundation (IBEF), in India, there were around 196,312 hospitals and 156,926 sub centres in 2015.
Major players active in the global sarcoma biopsy market are C. R. Bard, Inc., C. R. Bard, Inc., Becton, Argon Medical Devices, Dickinson and Company, Cook Medical Incorporated, UROMED, InVivo Therapeutics Corporation, and Sterylab.
Other Related Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027